OCTN2/SLC22A5 Antibody (893753) [DyLight 594]

• Reactivity: Hu
• Applications: Flow
• Clone: 893753
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: DyLight 594

OCTN2/SLC22A5 Antibody (893753) [DyLight 594] Summary

• Immunogen: NS0 transfected with human SLC22A5
  Accession # O76082
• Specificity: Detects human OCTN2/SLC22A5 in ELISA.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein A or G purified from hybridoma culture supernatant

Notes

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Alternate Names for OCTN2/SLC22A5 Antibody (893753) [DyLight 594]

• CDSP
• FLJ46769
• High-affinity sodium-dependent carnitine cotransporter
• OCTN2
• OCTN2high-affinity sodium dependent carnitine cotransporter
• OCTN2VT
• organic cation transporter 2
• organic cation transporter 5
• Organic cation/carnitine transporter 2
• SCD
• SLC22A5
• solute carrier family 22 (organic cation transporter), member 5
• solute carrier family 22 (organic cation/carnitine transporter), member 5
• solute carrier family 22 member 5

Background

Polyspecific organic cation transporters in the liver, kidney, intestine, and other organs are critical for elimination of many endogenous small organic cations as well as a wide array of drugs and environmental toxins. The encoded protein is a plasma integral membrane protein which functions both as an organic cation transporter and as a sodium-dependent high affinity carnitine transporter. The encoded protein is involved in the active cellular uptake of carnitine. Mutations in this gene are the cause of systemic primary carnitine deficiency (CDSP), an autosomal recessive disorder manifested early in life by hypoketotic hypoglycemia and acute metabolic decompensation, and later in life by skeletal myopathy or cardiomyopathy. [provided by RefSeq]

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.